Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZURA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsZura Bio reports Q1 2026 earnings, updates investor presentation
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
medium
Zura Bio announced first quarter 2026 financial results via press release on May 7, 2026. Actual financial figures are contained in the attached press release (Exhibit 99.1), not in the 8-K body itself.
Item 2.02 verify on EDGAR → -
low
Company released updated corporate presentation for use at upcoming investor conferences and meetings. This is a routine Regulation FD disclosure ensuring public access to materials shown to select audiences.
Item 7.01 verify on EDGAR →
Summary
Zura Bio filed a standard earnings announcement 8-K disclosing its first quarter 2026 financial results. The actual financial data appears in the attached press release rather than in the filing body, which is typical for quarterly earnings announcements. The company also provided an updated investor presentation intended for upcoming conferences and meetings, a routine disclosure under Regulation FD rules.
For retail investors, the key information is in the press release exhibit. Review it for revenue trends, cash position, clinical trial progress, and management guidance. The updated presentation may offer additional context on the company's strategic priorities and pipeline developments. Watch for any follow-on analyst calls or investor day announcements that could provide deeper insight into the quarter's performance and forward outlook.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 7, 2026, Zura Bio Limited (the “Company”) issued a press release announcing its first quarter 2026 financial results.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the press release as Exhibit 99.1. This is a standard earnings announcement filing.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On May 7, 2026, the Company provided an updated corporate presentation that may be used in connection with upcoming presentations at conferences and investor meetings.
The company released a refreshed investor presentation intended for use at conferences and investor meetings. This is a routine disclosure under Regulation FD to ensure fair public access to materials being shown to select audiences. The filing explicitly states this information is not deemed 'filed' under securities law and won't be incorporated by reference into other SEC filings.
Event · Item 9.01 — Financial Statements and Exhibits
Zura Bio filed an 8-K attaching a press release and corporate presentation dated May 7, 2026, with no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
99.1 Press Release dated May 7, 2026
99.2 Corporate Presentation, dated May 7, 2026
The company attached a press release and corporate presentation both dated May 7, 2026. The 8-K body does not describe the content of these exhibits, so the nature of the disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify